Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30934943 | 1.00 | KMT2A (0.41) | KMT2AMEN1MAPTHTTPOLB | |
| SCHEMBL1506443 | 0.83 | MAPT (0.39) | KMT2AMEN1MAPTPOLBALDH1A1 | |
| SCHEMBL19578797 | 0.81 | KMT2A (0.53) | KMT2AMEN1MAPTHTTALDH1A1 | |
| SCHEMBL31726663 | 0.81 | KMT2A (0.53) | KMT2AMEN1MAPTHTTALDH1A1 | |
| SCHEMBL19744030 | 0.81 | MAPT (0.35) | KMT2AMEN1MAPTPOLB | |
| SCHEMBL30934837 | 0.81 | MAPT (0.35) | KMT2AMEN1MAPTPOLB | |
| SCHEMBL16651200 | 0.78 | FFAR4 (0.35) | KMT2AMEN1MAPTHTTALDH1A1 | |
| SCHEMBL6524904 | 0.75 | KMT2A (0.44) | KMT2AMEN1MAPTHTTPOLB | |
| SCHEMBL16659005 | 0.75 | KDM4E (0.35) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL29495709 | 0.75 | KMT2A (0.44) | KMT2AMEN1MAPTHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| CN-114127073-B | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-21 | — | — | US | disclosed |
| EP-3999510-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114127073-A | Imidazopyrimidines as EED inhibitors and uses thereof | 美国密歇根州立大学试剂中心 | 2022-03-01 | — | — | CN | disclosed |
| WO-2021011713-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011713-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| EP-2934518-B1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| WO-2012058187-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | KMT2A 3921/4885MEN1 3533/4885MAPT 2376/4885 |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | KMT2A 1376/4885MEN1 1520/4885MAPT 4458/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | KMT2A 31/4885MEN1 630/4885MAPT 877/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | KMT2A 1376/4885MEN1 1520/4885MAPT 4458/4885 |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | KMT2A 1376/4885MEN1 1520/4885MAPT 4458/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | KMT2A 3577/4885MEN1 4462/4885MAPT 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.